Strategies in Mantle Cell Lymphoma

Fig. 1

Our approach to MCL treatment

Table 1

Frontline regimens in patients ≤70 years

Frontline regimen	Age (years)	ORR (%)	PFS/FFS	OS
R-Hyper-CVAD [16]	≤81	97	3 years 64 % (≤65 3 years 73 %)	3 years 82 %
R-Hyper-CVAD [17]	<70	86	5 years 49 %	5 years 63 %
R-Hyper-CVAD [19]	≤70	83	5 years 61 %	5 years 73 %
CALGB 59909 [21]	<70	88	5 years 56 %	5 years 64 %
CALGB 50403 [22]	<70	81	3 years 67 %
NLG MCL-2 [23]	≤66	96	6 years 66 %	6 years 70 %
GELA [26]	≤66	95	5 years 64 %	5 years 75 %
European MCL [27]	≤65	95	Median TTF 88 months	Median OS not reached

Table 2

Frontline regimens in patients ≥70 years

Frontline regimen	Age (years)	ORR (%)	PFS/FFS/TTF/DOR	OS
R-CHOP [34]	>60	78	TTF 28 months, median DOR 36 months	4 years 62 %
R-FC [34]	>60	86	TTF 26 months, median DOR 37 months	4 years 47 %
R-CHOP [35]	70 (median)	91	22.1 months (median)	Median not reached
BR [35]	70 (median)	93	35.4 months (median)	Median not reached
European older MCL [34] (R-CHOP + maintenance R)	>60	95	Median DOR >6 years	4 years 87 %

References

Swerdlow S, Campo E, Harris N et al (2008) WHO classification of tumors of hematopoietic and lymphoid tissues. World Health Organization, Lyon, pp 229–232

Anderson JR, Armitage JO et al (1998) Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s lymphoma classification project. Ann Oncol 9(7):717–720PubMedCrossRef

Zhou Y, Wang H et al (2008) Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancerb 113(4):791–798CrossRef

International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994CrossRef

Hoster E, Dreyling M, Klapper W et al (2008) A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood 111:558–565PubMedCrossRef

Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA et al (1996) p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87(8):3351–3359PubMed

Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR et al (1996) p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87(10):4302–4310PubMed

Martinez A, Bellosillo B, Bosch F, Ferrer A, Marce S, Villamor N et al (2004) Nuclear surviving expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164(2):501–510PubMedCentralPubMedCrossRef

Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E (2002) Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 69(1):11–20PubMedCrossRef

10.

Cohen JB, Ruppert AS, Heerema NA et al (2012) Complex Karyotype (CK) is associated with a shortened progression-free survival (PFS) in patients with newly diagnosed mantle cell lymphoma. Blood A:2691

11.

Sarkozy C, Terré C, Jardin F et al (2014) Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromo Cancer 53(1):106–116. doi:10.1002/gcc.22123 CrossRef

12.

Nodit L, Bahler D, Jacobs S et al (2003) Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 34:1030–1034PubMedCrossRef

Only gold members can continue reading. Log In or Register to continue